» Articles » PMID: 38087364

SPOCK1, As a Potential Prognostic and Therapeutic Biomarker for Lung Adenocarcinoma, is Associated with Epithelial-mesenchymal Transition and Immune Evasion

Overview
Journal J Transl Med
Publisher Biomed Central
Date 2023 Dec 13
PMID 38087364
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The occurrence of epithelial-mesenchymal transition (EMT) and immune evasion is considered to contribute to poor prognosis in lung adenocarcinoma (LUAD). Therefore, this study aims to explore the key oncogenes that promote EMT and immune evasion and reveal the expression patterns, prognostic value, and potential biological functions.

Methods: Firstly, we identified gene modules associated with EMT and Tumor Immune Dysfunction and Exclusion (TIDE) through weighted gene co-expression network analysis (WGCNA). Next, we utilized differential analysis and machine learning to identify the key genes and validate them. Moreover, we analyzed the correlation between key genes and tumor microenvironment remodeling, drug sensitivity, as well as mutation frequency. Furthermore, we explored and validated their malignant biological characteristics through in vitro experiments and clinical samples. Finally, potential drugs for LUAD were screened based on CMap and validated through experiments.

Results: Firstly, WGCNA analysis revealed that red and green modules were highly correlated with EMT and TIDE. Among them, upregulated expression of SPOCK1 was observed in lung adenocarcinoma tissues and was associated with poor prognosis. Additionally, patients in the high SPOCK1 group showed more activation of malignant oncogenic pathways, higher infiltration of immunosuppressive components, and a higher frequency of mutations. The knockdown of SPOCK1 suppressed invasion and metastasis capabilities of lung adenocarcinoma cells, and the high expression of SPOCK1 was associated with low infiltration of CD8 T cells. Therapeutic aspects, SPOCK1 can be a candidate indicator for drug sensitivity and CMap showed that VER-155008 was the drug candidate with the largest perturbation effect on the SPOCK1 expression profile. In vitro and in vivo experiments validated the cancer-inhibitory effect of VER-155008 in LUAD.

Conclusion: This study revealed through comprehensive bioinformatics analysis and experimental analysis that SPOCK1 can promote EMT and immune escape in LUAD, and it may serve as a promising candidate prognostic biomarker and therapeutic target for LUAD.

Citing Articles

Significance of in prognosis and tumor microenvironment of lung adenocarcinoma.

Wang N, Cao S, Tan X, Liu M Front Pharmacol. 2025; 16:1540636.

PMID: 40070576 PMC: 11893870. DOI: 10.3389/fphar.2025.1540636.


The Clinopathological and Prognostic Significance of in Gynecological Cancers: A Bioinformatics Based Analysis.

Karaman E, Yay F, Ayan D, Bayram E, Erturk S Biology (Basel). 2025; 14(2).

PMID: 40001977 PMC: 11852031. DOI: 10.3390/biology14020209.


Theoretical perspectives and clinical applications of non-coding RNA in lung cancer metastasis: a systematic review.

Yang J, Luo Y, Yao Z, Wang Z, Jiang K Discov Oncol. 2025; 16(1):169.

PMID: 39937377 PMC: 11822152. DOI: 10.1007/s12672-025-01919-3.


Roles of SPOCK1 in the Formation Mechanisms and Treatment of Non-Small-Cell Lung Cancer and Brain Metastases from Lung Cancer.

Zhang X, Zhang X, Yin H, Li Q, Fan B, Jiang B Onco Targets Ther. 2025; 18():35-47.

PMID: 39835273 PMC: 11745074. DOI: 10.2147/OTT.S483576.


A novel basement membrane-related gene signature for predicting prognosis of HNSCC.

Wang X, Wang Z Medicine (Baltimore). 2025; 104(3):e41316.

PMID: 39833042 PMC: 11749747. DOI: 10.1097/MD.0000000000041316.


References
1.
Massey A, Williamson D, Browne H, Murray J, Dokurno P, Shaw T . A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells. Cancer Chemother Pharmacol. 2009; 66(3):535-45. DOI: 10.1007/s00280-009-1194-3. View

2.
Wang M, Herbst R, Boshoff C . Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021; 27(8):1345-1356. DOI: 10.1038/s41591-021-01450-2. View

3.
Pastushenko I, Blanpain C . EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol. 2018; 29(3):212-226. DOI: 10.1016/j.tcb.2018.12.001. View

4.
Wang G, Xu D, Zhang Z, Li X, Shi J, Sun J . The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response. NPJ Precis Oncol. 2021; 5(1):56. PMC: 8219790. DOI: 10.1038/s41698-021-00200-4. View

5.
Herbst R, Morgensztern D, Boshoff C . The biology and management of non-small cell lung cancer. Nature. 2018; 553(7689):446-454. DOI: 10.1038/nature25183. View